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n ? p⁄ interaction
PROTACsa b s t r a c t
Thioamide substitution influences hydrogen bond and n? p⁄ interactions involved in the conformational
stability of protein secondary structures and oligopeptides. Hydroxyproline is the key recognition ele-
ment of small molecules targeting the von Hippel-Lindau (VHL) E3 ligase, which are of interest as probes
of hypoxia signaling and ligands for PROTAC conjugation. We hypothesized that VHL ligands could be a
privileged model system to evaluate the contribution of these interactions to protein:ligand complex for-
mation. Herein we report the synthesis of VHL ligands bearing thioamide substitutions at the central
hydroxyproline moiety, and characterize their binding by fluorescence polarization, isothermal titration
calorimetry, X-ray crystallography and molecular modeling. In spite of a conserved binding mode, the
substitution pattern had a pronounced impact on the ligand affinities. Together the results underscore
the role of hydrogen bond and n ? p⁄ interactions in fine tuning hydroxyproline recognition by VHL.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Thioamide is a well-known amide isosteric replacement.1
Despite the subtle differences between the two groups (amide
oxygen converted into a sulfur in thioamides), they present distinct
structural and biological properties.1 The length of the C@S bond
(1.65 Å) is known to be longer than the C@O bond (1.19–1.25 Å)
due to the larger size of the sulfur atom.2,3 Additionally in thioa-
mides the NAH group acts as a stronger hydrogen bond donor than
in its amide congener, and vice versa the sulfur acts as a weaker
hydrogen bond acceptor than the oxygen carbonyl.4 In fact, previ-
ous studies revealed that the hydrogen bond interaction in O is
dominated by a charge-charge attraction, whereas in S the interac-
tion is mainly stabilized by a weaker charge-quadrupole.5 The
O-to-S substitution has been widely applied to investigate the
contribution of hydrogen bond formation to protein secondary
structures.6–11 In contrast, thioamide replacement to probe
protein–ligand interactions remains understudied.
In addition to affecting hydrogen bonding, thioamide substitu-
tion also modulates the strength of the n ? p⁄ interaction,1,12,13
which has been identified in several systems, including proteins
and small molecules.1,10,12–16 In this interaction the lone pair (n)
of a donor group (carbonyl oxygen or thiocarbonyl sulfur) overlaps
with the antibonding orbital (p⁄) of an acceptor group (a second
carbonyl or thiocarbonyl). This overlap is maximized when the
donor and acceptor groups form a short contact in theBürgi–Dunitz trajectory (107, Fig. 1A).12,15,17 Conversion of the
donor group from O to a softer base such as S increases the
n ? p⁄ electronic delocalization.12 Hence thioamides are better
electron-pair donors, increasing the strength of the interaction.12
In recent years a series of potent, selective and cell-active inhi-
bitors of the von Hippel-Lindau (VHL) E3 ubiquitin ligase have
been designed and optimized around a key hydroxyproline (Hyp)
anchor fragment.18–21 VHL inhibitors act on their own as chemical
probes of hypoxia signaling.22 In addition, VHL ligands are widely
used as E3 ligase ligands for PROTAC (proteolysis-targeting chimera)
conjugation, a strategy for targeted protein degradation.23–28 The
modified Hyp residue is crucial also for the recognition of the
hypoxia inducible factor 1 alpha subunit (HIF-1a), the natural
substrate of VHL.29,30 A closer analysis of the X-ray co-crystal
structure of VHL, elongin B, elongin C (VBC) in complex with
inhibitor VH032 (PDB 4W9H)20 and HIF-1a peptide (PDB 4AJY)19,
suggested a conformation compatible with an n ? p⁄ interaction
between the two amide carbonyl groups around the hydroxypro-
line core (Fig. 1B). We therefore hypothesized that this protein–
ligand system could be probed through thioamide substitution.
We began by designing a series of thioamide derivatives of the
model VHL ligand 1,21 bearing single as well as double O-to-S sub-
stitutions (Fig. 2). The general procedure for the synthesis of thioa-
mide derivatives 2–4 is summarized in Scheme 1 and briefly
described in the following paragraph (see Supporting information
for detailed synthesis protocols and Supp. Figs. 1–3 for NMR
spectra).
Fig. 1. n ? p* interaction in prolines and VHL inhibitors. A) Notion of proline
backbone carbonyl-carbonyl n ? p* interaction. B) Crystal structure of VBC
(omitted) in complex with inhibitor VH032 (green carbons) (PDB 4W9H). Possible
n ? p* interaction in VHL ligands is shown as a black dashed line.
Fig. 2. Chemical structure of inhibitor 1 and thioamide derivatives 2–4.
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ate 5, which was synthesized as previously described.20 Boc depro-
tection of 5 followed by amide coupling with thioamide derivative
A ((S)-tert-Butyl (1-(6-nitro-1H-benzo[d][1,2,3]triazol-1-yl)-1-
thioxopropan-2-yl)carbamate, prepared according to literature31)
led to intermediate 7 (71%). Boc deprotection of this intermediate
followed by acylation yielded the final compound 3 (76%), bearing
a single thioamide at the left-hand side. To introduce the O-to-S
substitution at the right-hand side, the Hyp hydroxyl group of
intermediate 5 was first protected with TBSCl, followed by thioa-
mide conversion to give intermediate 6 (68%). Subsequent Boc
deprotection of 6 and HATU (1-[Bis(dimethylamino)methylene]-
1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate)-
assisted amide coupling with Boc-protected alanine led to 8
(75%). Boc deprotection of 8 followed by acylation yielded the final
thioamide 2 (69%). To obtain the final doubly substituted com-
pound, deprotected intermediate 6 was reacted with thioamide
derivative A to give intermediate 9 (49%). Boc deprotection of this
intermediate followed by acylation led to the final thioamide
derivative 4 (64%).Scheme 1. Synthesis of thioamide compounds 2–4. (i) TFA:DCM (3:7), r.t., 1 h; (ii) activat
TBSCl, imidazole, DMF, r.t., o.n.; (v) ammonium O,O’-diethyl dithiophosphate, toluene, reWe also attempted to introduce the thioamide substitution on a
more potent analogue of compound 1, the VHL inhibitor VH032,
which bears a tert-leucine moiety instead of an alanine.20–22 How-
ever the conversion of the amide on the left-hand side of the
hydroxyproline core was not accomplished. In fact, as observed
by Engel-Andreasen et al.,32 the presence of the hindered tert-butyl
group near a carbonyl could prevent its conversion to thiocarbonyl.
The binding affinity of the newly synthesized compounds to
VHL was evaluated by two orthogonal assays: a direct binding
assay using isothermal titration calorimetry (ITC) and a competi-
tion assay using fluorescence polarization (FP), which monitored
the compound’s ability to displace a fluorescently-labeled high-
affinity HIF peptide (Table 1). The results from both assays revealed
an excellent agreement on the compounds affinity rank (Fig. 3A
and B). The highest affinity compound 3, which bears a single
thioamide conversion at the left-hand side, revealed comparable
binding to the unmodified ligand 1, with only a small twofold loss
in binding affinity, as measured by both techniques. In contrast,
ligand 2 (single right-hand side thioamide) showed a greater loss
in binding affinity (10-fold loss by FP, and 20-fold loss by ITC).
Double substitution in ligand 4 resulted in the weakest binder of
this series, with Kd > 10 lM.
We next evaluated the impact of thioamide substitutions to the
n? p⁄ interaction in the ligand free state in solution. This interac-
tion is only possible when the Hyp (thio)amide group is in the trans
isomer conformation (Fig. 1A). Thus, the ratio between the trans
and cis isomers at equilibrium can be used to infer the strength
of the n? p⁄ interaction.13 Since both cis and trans isomers of pro-
line backbone amides are populated at room temperature, they can
be monitored by NMR spectroscopy due to their slow interconver-
sion, as demonstrated by Newberry et. al.13 The NMR results
(Table 1) revealed a small decrease on the trans isomer when the
acceptor group was substituted by a thioamide (2) and vice versa
a small increase of this isomer was observed when the substitution
was made on the donor group (3). This results support the stronger
n ? p⁄ donor character of thioamides when compared with
amides.12,13 However, in contrast to what is observed for simple
proline models13,14, only modest differences in trans isomer stabi-
lization in compounds 2 and 3 could be observed (between ±2–3%).
We performed density functional theory (DFT) calculations of
the n ? p⁄ contribution in model compounds 10–13, in which
the substituents at the right- and left-hand side of inhibitors 1–4
were omitted for simplicity (see Supp. Figs. 6 and 7). The results,
summarized in Table 1 (see Supp. Table 2 for full details), show
that the donor sulfur compound 12 presents an n ? p⁄ stabiliza-
tion energy (En?p⁄) of 2.6 kcal/mol, higher than the parent
derivatives 10 and 11 and in good agreement with the NMR results.ed thioamide (A), DIPEA, DMF, r.t., 3 h; (iii) acetic anhydride, Et3N, DCM, r.t., 3 h; (iv)
flux, o.n.; (vi) TFA:DCM (1:9), r.t., 2 h; (vii) Boc-Ala-OH, HATU, DIPEA, DMF, r.t., 2 h.
Table 1
SAR results and computational data of compounds 1–4. FP back calculated Kds, ITC measured Kds and DH; % of observed trans and cis isomers in solution measured by NMR;
stabilization energy of the n ? p* interaction quantified by DFT calculations in model compounds 10–13 (see Supp. Fig. 6); and estimation of interaction energies of the











Rel. EMM-GBSA of Tyr98
(kcal/mol)
Rel. EMM-GBSA of Tyr112
(kcal/mol)
1 0.69 ± 0.03 0.44 ± 0.04 9.12 ± 0.07 92:8 2.1 110.9 – –
2 7.07 ± 0.10 9.4 ± 0.3 5.37 ± 0.05 89:11 2.0 103.7 2.3 0.0
3 1.0 ± 0.4 0.76 ± 0.02 6.79 ± 0.01 kcal/mol 94:6 2.6 104.9 0.1 0.1
4 >13 21.6 ± 0.8 2.56 ± 0.01 90:10 3.4 98.4 3.3 0.8
Fig. 3. Biophysical characterization of compounds 1–4 binding to VHL. A) Competitive fluorescence polarization binding assay curve of compounds displacing a 20-mer FAM-
labeled HIF-1a peptide bound to VBC (Kd = 3 nM). B) ITC direct titration of compounds into VBC protein complex. C) Predicted EMM-GBSA versus experimental DH for
compounds 1–4 binding to VBC.
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are converted to thiocarbonyls, is further increased to 3.4 kcal/mol,
indicating a better overlap of the corresponding molecular orbitals
in this compound, and consistent with previous calculations by
Newberry et al.13 Those results would suggest that 4 should have
the highest population of trans isomer among the studied com-
pounds. Conversely, full thioamide replacement in compound 1
to yield compound 4 led to an unexpected 2% decrease on the trans
isomer as observed by NMR. Therefore, the conformational prefer-
ences of larger compounds 1–4 cannot be reliably studied using
surrogate model compounds 10–13. Importantly, the trans:cis
ratios as observed by NMR did not correlate with binding affinities.
This motivated us to carry out a detailed crystallographic analysis
of the VHL:inhibitor interactions to provide structural insights on
the observed differences in binding affinities.
We obtained high-resolution X-ray crystal structures of com-
pounds 2–4 in complexwith VBC (see Supp. Fig. 4, see Supp. Table 1
for data collection and refinement statistics). The omit difference
electron density (Fo–Fc) observed unambiguously identified the
inhibitor bound at the expected VHL site (Fig. 4A and Supp.
Fig. 5). The new structures revealed that the noncovalent interac-
tion network between the compounds and VHL residues was fully
conserved and consistent with those observed with previous inhi-
bitors (Fig. 4B).20 Superposition of the crystal structures of VBC in
complex with compounds 1–4 also revealed that thioamide con-
version induced a slight change in the position of the Tyr112 side
chain (Fig. 4C). The presence of the thioamide on the left-hand side
of Hyp resulted in Tyr112 bending slightly to accommodate the
bulkier group. Additionally we measured the hydrogen bond dis-
tances between the compounds right-hand side O/S acceptor
groups and the side chain hydroxyl of Tyr98. An increase in hydro-
gen bond distances was observed for compounds 2 and 4 (3.0 ± 0.1
and 2.95 ± 0.05 Å for O–H  S@C groups, respectively) compared to
1 and 3 (2.52 ± 0.05 Å for O–H  O@C groups, on both compounds).
This trend could be explained by the increased van der Walls
radius and decreased electronegativity of sulfur compared to oxy-
gen5, and is consistent with the thioamide group being a weakerhydrogen bond acceptor compared to the amide group.33 Together,
our data reveal a key role of the Tyr98 side chain hydrogen bond in
VHL ligand binding.
We next performed molecular mechanics calculations on each
of the ligand:VHL complexes using the generalized-Born surface
area (MM-GBSA) approximation and estimated interaction ener-
gies (EMM-GBSA) between the ligands and the protein. The predicted
EMM-GBSA values are in excellent agreement with experimental
enthalpic contributions to binding (DH, Fig. 3C), and in good agree-
ment with Gibbs free energies (DG, Supp. Fig. 8). We therefore
evaluated the interaction energy of each protein amino acid in
the complexes with its surrounding to determine differences in rel-
ative EMM-GBSA compared to reference inhibitor 1. The results,
shown in Table 1, indicate that the loss in binding affinity observed
in compounds 2 and 4 is largely contributed by destabilization of
Tyr98 and, to a much lesser extent, of Tyr112, especially in com-
pound 4. Thus, the molecular modeling calculations provided a
solid computational model to predict the impact of O-to-S substi-
tutions of amides in binding affinity and enabled quantification
of the subtle structural changes observed in the crystal structures
of VHL in complex with the inhibitors.
In summary we describe the synthesis and biophysical charac-
terization of a series of thioamide derivatives of a potent VHL inhi-
bitor. In spite of a fully conserved binding mode, the pattern of
substitution had markedly varying effects on binding affinities.
Substitution at the left-hand side amide was tolerated, while sub-
stitution at the right-hand side had the most detrimental effect,
highlighting the prevalent role of the Tyr98 hydrogen bond in
molecular recognition. Molecular modeling calculations could
recapitulate the trends in binding affinities observed experimen-
tally and provided a theoretical framework for understanding the
subtle structural changes observed crystallographically. The results
of this study could prove useful to future drug design of VHL inhi-
bitors for PROTACs. More generally, we provide a combined bio-
physical, structural and modeling characterization cascade that
could be applied to study the role of thioamide substitutions in
other protein–ligand interaction systems.
Fig. 4. Co-crystal structures of compounds 1–4 in complex with VBC. A) The omit difference electron density (Fo-Fc) superimposed around 3 is shown in blue contoured at 3r
and with a 2.0 Å carve radius. B) Detailed binding interactions of compound 3 (yellow carbons) with VHL pocket residues. VHL residues forming the binding pocket are shown
as orange stick representations. Water forming hydrogen bond with the compound is shown as a red sphere. Hydrogen bond interactions between compound, bound waters
and VHL pocket residues are shown as black dashed lines. C) Superposition of VBC structures in complex with compounds 1 (green carbons), 2 (light blue carbons), 3 (yellow
carbons) and 4 (purple carbons) showing details of VHL binding pocket. Residues around hydroxyproline core are presented with the same color as the respective bound
compounds. Hydrogen bond interaction between compounds and Tyr98 is shown as black dashed lines.
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